Immune checkpoint blockade as a potential therapeutic target: Surveying CNS malignancies

Neuro-Oncology

Volumn 18, Issue 10, 2016, Pages 1357-1366

  Garber, Sarah T ^a   Hashimoto, Yuuri ^a   Weathers, Shiao Pei ^a   Xiu, Joanne ^b   Gatalica, Zoran ^b   Verhaak, Roel G W ^a   Zhou, Shouhao ^a   Fuller, Gregory N ^a   Khasraw, Mustafa ^c   De Groot, John ^a   Reddy, Sandeep K ^a   Spetzler, David ^a   Heimberger, Amy B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CARIS LIFE SCIENCES   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

glioblastoma; immune checkpoint; low grade glioma; PD 1; PD L1

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN P53; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CELL; CANCER GRADING; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHROMOSOME 19Q; CHROMOSOME 1P; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; PRESCHOOL CHILD; PYROSEQUENCING; SCHOOL CHILD; VERY ELDERLY; BIOSYNTHESIS; BRAIN TUMOR; GENETICS; GLIOMA; HIGH THROUGHPUT SEQUENCING; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOMA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MUTATION; PROGRAMMED CELL DEATH 1 RECEPTOR; YOUNG ADULT;

EID: 84991396048     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now132     Document Type: Article

References (37)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. Preusser M, de Ribaupierre S,Wohrer A, et al. Current concepts and management of glioblastoma. Ann Neurol. 2011;70(1):9-21.
3. Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17(8):1064-1075.
4. Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18(2):195-205.
5. Preusser M, Berghoff AS, Wick W, et al. Clinical neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma? Clin Neuropathol. 2015;34(6):313-321.
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
7. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571.
8. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-1920.
9. Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2965-2970.
10. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009;15(14): 4622-4629.
11. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003.
12. Quillien V, Lavenu A, Karayan-Tapon L, et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer. 2012;118(17):4201-4211.
13. Agresti A. Categorical Data Analysis, 2nd ed. New York: John Wiley & Sons; 2003.
14. Gelman A, Carlin J, Stern HS, et al. Bayesian Data Analysis, 2nd ed. New York: Chapman & Hall/CRC Press; 2003.
15. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc. 1995;57(1):289-300.
16. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5): 283-296.
17. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84-88.
18. Martins FC, Santiago I, Trinh A, et al. Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol. 2014;15(12):526.
19. Ogura R, Tsukamoto Y, Natsumeda M, et al. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas. Neuropathology. 2015;35(4):324-335.
20. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
21. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11(4):1462-1466.
22. Dasgupta T, Olow AK, Yang X, et al. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol. 2016;126(3):385-393.
23. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
24. Kim H, Zheng S, Amini SS, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25(3): 316-327.
25. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008;14(16):5166-5172.
26. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514): 324-327.
27. England B, Huang T, Karsy M. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol. 2013;34(4):2063-2074.
28. Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011;13(3): 324-333.
29. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-421.
30. Gupte M, Tuck AN, Sharma VP, et al. Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator. PLoS One. 2013; 8(9):e74071.
31. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189-193.
32. Xu C, Fillmore CM, Koyama S, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014;25(5):590-604.
33. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577-581.
34. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-128.
35. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199.
36. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567.
37. Avkin S, Sevilya Z, Toube L, et al. p53 and p21 regulate error-prone DNA repair to yield a lower mutation load. Mol Cell. 2006;22(3): 407-413.